The Topical Drug Delivery Market is expected to witness a CAGR of 8.5%, during the forecast period. With the delay in diagnosis and treatment, a significant impact on the topical drug demand was also observed. However, several clinical studies for topical treatments in COVID-19 are being carried out which is expected to aid the market studied. For instance, in June 2020, researchers from Mansoura University initiated a clinical study with respect to a topical steroid and cyclosporin-A for the treatment of COVID-19 keratoconjunctivitis.
The prevalence of skin infections, like eczema, psoriasis, etc., and minor ailments, like acne, are increasing and having a big impact on the market globally. Psoriasis effect is observed in people of all ages, and in all countries. According to the study titled, ''National, regional, and worldwide epidemiology of psoriasis: a systematic analysis and modeling study'', in May 2020, the incidence of psoriasis in adults was estimated to be around 30.3 per 100,000 person-years in Taiwan and about 321.0 per 100 000 person-years in Italy. Thus, in different geographic regions, with increased population sizes, there is a significant burden related to the skin which is diagnosed at a prominent stage, and in such cases, the topic of drug delivery becomes more important. Hence, these statistics show that skin disease prevalence is increasing at a faster pace and is becoming a global burden, which is likely to positively impact the growth of the topical drug delivery market.
Some of the other factor that drives the market includes the ease of drug delivery, and technological advancements and innovations. In March 2019, Amneal Pharmaceuticals introduced the generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. It is used for the treatment of dementia caused due to Alzheimer's and Parkinson's disease. Such innovations are expected to flourish the market growth over the forecast period.
However, the factors such as regulatory scenario and pricing pressure along with high frequency of product recalls is expected to obstruct the market studied. In November 2020, Health Canada recalled Picato developed by Leo Pharma Inc. a topical drug used to treat skin lesions as this drug may have the potential to increase the risk of non-melanoma skin cancer. Thus, it can restrict the market growth.
Key Market Trends
Patch Segment is Expected to Hold Major Share in the Topical Drug Delivery Market
Patches in the Devices segment are expected to hold a major share in the Topical Drug Delivery market. Due to the emergence of COVID-19, a profound impact on the patch was also observed. In July 2020, Innoture received funding from the Welsh Government of about GBP 200,000 for its project: ''Self-Administration of SARS-CoV-2 Vaccine via Microlithographic 3D printed Microstructure Patches''. Such developments are expected to accelerate market growth in this segment.
There have been significant advantages associated with the skin patches that target a particular site in the body. The administration of drugs through the skin is also performed to achieve controlled or prolonged drug delivery and this route can be explored as an alternative to the oral route.
With the increasing product launches, the market studied is expected to flourish in this segment. For instance, in June 2020, Vektor Pharma introduced a generic version of Neupro patch (rotigotine), a transdermal patch that indicated against the symptoms of Parkinson's disease.
Furthermore, in December 2020, Agile Therapeutics, Inc. introduced Twirla (levonorgestrel and ethinyl estradiol) transdermal system which is a contraceptive patch. In October 2019, United States Food & Drug Administration approved ''SECUADO (asenapine) transdermal system'' developed by Noven Pharmaceutical Inc. (Hisamitsu Pharmaceutical Co., Inc.). It is the only transdermal patch formulation which has been approved for the treatment of adults with schizophrenia. Thus, with the rising number of product launches along with the advantages associated with skin patches the market studied is expected to boost in this segment.
North America is Expected to Dominate the Market Over the Forecast Period
North America has been accounted for the highest share in the Topical Drug Delivery market. Due to the outbreak of COVID-19, the market is expecting to observe positive growth. This is mainly due to the novel treatment being developed. For instance, in August 2020, the United States Food and Drug Administration approved an over-the-counter ointment ''T3X'' developed by Advanced Penetration Technology. It has been approved against the SARS-CoV-2 virus. The studies have shown that T3X was successfully able to kill the virus within 30 seconds.
Owing to the factors such as the presence of a large number of pharmaceutical companies and drug delivery technology providers. As per the data provided by GLOBOCAN, 2020, about 105,000 new cases of melanoma skin cancer were reported in the North American region which is expected to reach 142,000 by the year 2040. This growing burden of skin-related conditions is expected to accelerate the market growth.
Furthermore, growing product launches are also expected to boost the market growth in this region. For instance, in August 2020, the United States Food and Drug Administration (US FDA) approved Winlevi (clascoterone cream 1%) developed by Cassiopea SpA’s for the treatment of acne. Thus, aforementioned factors are expected to thrive the market growth in this region during the forecast period.
Competitive Landscape
The Topical Drug Delivery Market is moderately fragmented. The major players in the topical drug delivery market include - Bayer AG, Cipla, Mylan N.V, GlaxoSmithKline plc, Galderma Holding SA, Novartis, Med pharm, Johnson & Johnson (Janssen Pharmaceutical), Hisamitsu Pharmaceuticals, etc. provides these products across the globe.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
The prevalence of skin infections, like eczema, psoriasis, etc., and minor ailments, like acne, are increasing and having a big impact on the market globally. Psoriasis effect is observed in people of all ages, and in all countries. According to the study titled, ''National, regional, and worldwide epidemiology of psoriasis: a systematic analysis and modeling study'', in May 2020, the incidence of psoriasis in adults was estimated to be around 30.3 per 100,000 person-years in Taiwan and about 321.0 per 100 000 person-years in Italy. Thus, in different geographic regions, with increased population sizes, there is a significant burden related to the skin which is diagnosed at a prominent stage, and in such cases, the topic of drug delivery becomes more important. Hence, these statistics show that skin disease prevalence is increasing at a faster pace and is becoming a global burden, which is likely to positively impact the growth of the topical drug delivery market.
Some of the other factor that drives the market includes the ease of drug delivery, and technological advancements and innovations. In March 2019, Amneal Pharmaceuticals introduced the generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. It is used for the treatment of dementia caused due to Alzheimer's and Parkinson's disease. Such innovations are expected to flourish the market growth over the forecast period.
However, the factors such as regulatory scenario and pricing pressure along with high frequency of product recalls is expected to obstruct the market studied. In November 2020, Health Canada recalled Picato developed by Leo Pharma Inc. a topical drug used to treat skin lesions as this drug may have the potential to increase the risk of non-melanoma skin cancer. Thus, it can restrict the market growth.
Key Market Trends
Patch Segment is Expected to Hold Major Share in the Topical Drug Delivery Market
Patches in the Devices segment are expected to hold a major share in the Topical Drug Delivery market. Due to the emergence of COVID-19, a profound impact on the patch was also observed. In July 2020, Innoture received funding from the Welsh Government of about GBP 200,000 for its project: ''Self-Administration of SARS-CoV-2 Vaccine via Microlithographic 3D printed Microstructure Patches''. Such developments are expected to accelerate market growth in this segment.
There have been significant advantages associated with the skin patches that target a particular site in the body. The administration of drugs through the skin is also performed to achieve controlled or prolonged drug delivery and this route can be explored as an alternative to the oral route.
With the increasing product launches, the market studied is expected to flourish in this segment. For instance, in June 2020, Vektor Pharma introduced a generic version of Neupro patch (rotigotine), a transdermal patch that indicated against the symptoms of Parkinson's disease.
Furthermore, in December 2020, Agile Therapeutics, Inc. introduced Twirla (levonorgestrel and ethinyl estradiol) transdermal system which is a contraceptive patch. In October 2019, United States Food & Drug Administration approved ''SECUADO (asenapine) transdermal system'' developed by Noven Pharmaceutical Inc. (Hisamitsu Pharmaceutical Co., Inc.). It is the only transdermal patch formulation which has been approved for the treatment of adults with schizophrenia. Thus, with the rising number of product launches along with the advantages associated with skin patches the market studied is expected to boost in this segment.
North America is Expected to Dominate the Market Over the Forecast Period
North America has been accounted for the highest share in the Topical Drug Delivery market. Due to the outbreak of COVID-19, the market is expecting to observe positive growth. This is mainly due to the novel treatment being developed. For instance, in August 2020, the United States Food and Drug Administration approved an over-the-counter ointment ''T3X'' developed by Advanced Penetration Technology. It has been approved against the SARS-CoV-2 virus. The studies have shown that T3X was successfully able to kill the virus within 30 seconds.
Owing to the factors such as the presence of a large number of pharmaceutical companies and drug delivery technology providers. As per the data provided by GLOBOCAN, 2020, about 105,000 new cases of melanoma skin cancer were reported in the North American region which is expected to reach 142,000 by the year 2040. This growing burden of skin-related conditions is expected to accelerate the market growth.
Furthermore, growing product launches are also expected to boost the market growth in this region. For instance, in August 2020, the United States Food and Drug Administration (US FDA) approved Winlevi (clascoterone cream 1%) developed by Cassiopea SpA’s for the treatment of acne. Thus, aforementioned factors are expected to thrive the market growth in this region during the forecast period.
Competitive Landscape
The Topical Drug Delivery Market is moderately fragmented. The major players in the topical drug delivery market include - Bayer AG, Cipla, Mylan N.V, GlaxoSmithKline plc, Galderma Holding SA, Novartis, Med pharm, Johnson & Johnson (Janssen Pharmaceutical), Hisamitsu Pharmaceuticals, etc. provides these products across the globe.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Cipla Limited
- Mylan N.V.
- Glaxosmithkline plc
- Hisamitsu Pharmaceuticals
- Johnson & Johnson (Janssen Pharmaceutical)
- Medpharm
- Galderma Holding SA
- Novartis International AG
- Bausch Health Companies Inc.
- 3M
- Pfizer Inc.
Methodology
LOADING...
